Medical Condition

hepatocellular carcinoma hcc

Total Trials

16

Recruiting Now

16

Trial Phases

Phase 2, Phase 1, Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for hepatocellular carcinoma hcc sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — hepatocellular carcinoma hcc Clinical Trials

How many clinical trials are currently recruiting for hepatocellular carcinoma hcc?

ClinicalMetric currently tracks 16 actively recruiting clinical trials for hepatocellular carcinoma hcc, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 16. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for hepatocellular carcinoma hcc?

hepatocellular carcinoma hcc research spans Phase 1 (5 trials), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a hepatocellular carcinoma hcc clinical trial?

Eligibility criteria for hepatocellular carcinoma hcc trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

Fudan University 2 trials

Akeso 1 trial

City of Hope Medical Center 1 trial

VA Office of Research and Development 1 trial

Seoul National University Hospital 1 trial

hepatocellular carcinoma hcc

Frequently Asked Questions — hepatocellular carcinoma hcc Clinical Trials

Recruiting Clinical Trials

A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma

PSMA PET for the Staging and Management of Hepatocellular Carcinoma

Streamlining Radioembolization for Small HCC

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular Carcinoma

Computer Guided Microwave Liver Ablation

To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors

Predicting Immunotherapy Response and Survival of Liver Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Liver)

HAIC Combined With Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03)

NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy

Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma

Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, BTC or NEN